Category: Finance
-
ARPA-E Challenge Seeks Bio Energy Measurement Techniques
A new challenge on InnoCentive, sponsored by Advanced Research Projects Agency – Energy (ARPA-E), a division of the U.S. Department of Energy, is seeking new ideas for measuring the potential energy output of biofuel feedstocks, without harming the plant material. The competition, which has a maximum prize of $30,000, requires a written proposal and has…
-
Bayer Acquires Cancer Drug Developer Algeta for $2.9B
The global pharmaceutical company Bayer Group based in Germany is buying the specialty drug company Algeta ASA in Oslo, Norway for NOK 17.6 billion (USD 2.9 billion). Algeta, developer of a radium-based drug to treat prostate cancer, says its board of directors approved the sale, subject to confirmation by shareholders. Bayer and Algeta collaborated on…
-
NIH Giving In-Kind Technical Services for Rare Diseases
National Institutes of Health (NIH) is supporting three new projects with technical research services for two companies and one university lab developing therapies for rare diseases. The projects aim to develop treatments for acute radiation syndrome, brain injury following cardiac arrest, and beta thalassemia, a rare blood disorder. The awards are a product of the…
-
Injectable Therapy for Rotator Cuff Injuries in Development
Biomedical engineers at Georgia Institute of Technology in Atlanta are developing a material to be injected into torn rotator cuff tendons, a common sports injury, to speed their healing. The five-year project is led by Georgia Tech’s biomedical engineering professor Johnna Temenoff and funded by a $1 million grant from National Institute of Arthritis and…
-
Genome Editing Start-Up Secures $43M in First Round Funds
The Cambridge, Massachusetts start-up Editas Medicine, developing therapies based on new research in genome editing, gained $43 million in its first financing round. The funding was led by venture companies Flagship Ventures, Polaris Partners, and Third Rock Ventures, with participation from Partners Innovation Fund, the venture funding arm of Massachusetts General Hospital and Brigham and…
-
Challenge Seeks Endothelial Progenitor Cell Culture Process
A new challenge on InnoCentive is seeking a technique for storing and growing endothelial progenitor cells captured from blood samples and vital for research on and testing for various disorders. The competition has a purse of $25,000 and a deadline of 5 January 2014 for submissions. InnoCentive in Waltham, Massachusetts conducts open-innovation, crowd-sourcing competitions for…
-
Inflammation Drug Biotech Lands $32.4M in Venture Funding
Catabasis Pharmaceuticals Inc., a clinical-stage biotechnology company in Cambridge, Massachusetts, completed its second venture funding round, securing $32.4 million. The round was led by new investor Lightstone Ventures, with participation by the company’s current investors: SV Life Sciences, Clarus Ventures, MedImmune Ventures, and Advanced Technology Ventures. Catabasis Pharmaceuticals develops medications to treat cardiovascular, metabolic and inflammatory…
-
Research Consortium Applies X-ray Lasers to Drug Molecules
A group of eight universities and research institutes in the U.S. is advancing the use of X-ray laser technology in biology, with direct applications in finding molecular targets for new therapies. The Center for Biology with X-ray Laser, or BioXFEL, is funded by a $25 million grant from National Science Foundation, led by University at…
-
Strategy Sought to Encourage New Anticoagulant Prescriptions
A new challenge on InnoCentive is looking for new ways to encourage physicians to prescribe anticoagulant drugs other than the commonly used warfarin for decreasing the formation of blood clots in people with atrial fibrillation. The competition has a total purse of $7,500 and a deadline of 27 November 2013. InnoCentive in Waltham, Massachusetts conducts…
-
Contract Awarded for Influenza Vaccine and Immune Booster
NanoBio Corporation in Ann Arbor, Michigan received a new contract from National Institute of Allergy and Infectious Diseases, part of National Institutes of Health, for development of a pandemic influenza vaccine and adjuvant to boost the immune response of that vaccine. The initial contract value is $5.5 million, but the company says it would be…